New review article by Prof. Francesco Bertoni on BET inhibitors

news on 17 Jun , 2019
Prof. Francesco Bertoni and his Colleague PD Anastasios Stathis of the Oncology Institute of Southern Switzerland (IOSI) has just been published a review article that summarizes the current knowledge on BET inhibitors in lymphomas. The article is based on the talk given at the 2018 “Inaugural AACR International Meeting Advances in Malignant Lymphoma”, a conference organized in cooperation with the...

Cancer research: IOR receives important grant

news on 12 Jun , 2019
Proteins in cells are subject to various chemical modifications that regulate their activity. One common modification consists in the attachment of ubiquitin molecules through a cascade of enzymes. Genetic defects in this ubiquitin cascade are the cause of many acquired and hereditary diseases, including neurodegenerative, immune and tumour disorders. Due to the complex biology and transient natur...

A new paper by Prof. Francesco Bertoni’s lab on a dual TORC1/2 inhibitor

news on 6 Jun , 2019
The research team led by Prof. Francesco Bertoni has published the results of a project in collaboration with the Group of Prof. Wymann at the University of Basel and the Colleagues at PIQUR Therapeutics in the journal Cancers. mTOR is an atypical serine/threonine kinase often aberrantly activated in cancer cells because it is central in the regulation of cellular growth and metabolism. It is p...

New paper from Catapano and Carbone groups

news on 24 May , 2019
The study published in Cell Metabolism reveals new way to eliminate cancer stem cells in prostate cancer and enhance treatment efficacy. The study conducted by investigators in the Catapano and Carbone groups at the Institute of Oncology Research (IOR, affiliated to USI Università della Svizzera italiana) in Bellinzona, Switzerland, finds a new way to eliminate cancer stem cells in prostate ca...

Two new papers by Prof. Francesco Bertoni’s lab

news on 20 May , 2019
The research team led by Prof. Francesco Bertoni has recently added information on our knowledge of two hematological malignancies: MALT Lymphoma and Peripheral T-cell lymphoma. The results have been published in Haematologica and Modern Pathology, respectively. Using high-throughput sequencing techniques (DNA copy number analysis, targeted DNA sequencing, DNA methylation and RNA-sequencing), D...

First Castelgrande Lecture, Prof. Douglas Hanahan

news on 15 Apr , 2019
The IOR is pride to welcome Douglas Hanahan, Professor at the Swiss Federal Institute of Technology of Lausanne and Director of the Swiss Institute for Experimental Cancer Research (ISREC) to the first Castelgrande Lecture. With his lecture "“Hallmarks of Cancer: Thinking globally about new cancer therapies” Prof. Hanahan will discuss the challenges that future generations will have to face in ...